
    
      This is a prospective, parallel, randomized, open labeled, multicenter phase III clinical
      trial to compare the survival and toxicity of TPC VS PF as induction chemotherapy combined
      with CCRT for stage IVa-b nasopharyngeal carcinoma patients in endemic area.The primary
      endpoint is failure free survival (FFS）.The secondary endpoints are overall
      survival(OS）,progression-free survival（PFS）, local-regionally relapse free survival(LRFS),
      distant metastasis free survival（DMFS)and toxicities.
    
  